Dana Cohen is a senior manager with vast experience in the private and public biotech industry. Currently she is the CEO of DiagKnowstics and also the head of personalized & predictive medicine at ZOTAL. Prior to that she was the founder, inventor and CEO of BioMarCare Technologies (Companion Diagnostics) , CEO of TKsignal (pioneering development of radioactive biomarkers for PET/CT imaging) and a marketing manager at Pronto Diagnostics (genetic diseases diagnosis).
Dana brings a profound clinical and medical experience within a wide spectrum of diseases. She is specialized in clinical oncology and cancer markers, biotherapies in gastroenterology, drug monitoring (TDM), chimerism in Allogeneic hematopoietic cell transplantation , radio-pharmaceuticals, microbiome processing, anti-psychotic drugs, water pathogens and medical Cannabis. Comprehensive knowledge in multiple aspects of personalized medicine ranging from research, development, clinical trials and biobanking. Dana has a GCP for Investigators diploma and she graduated the Paul Merage Institute- Israel Lean Lauchpad program and competition 2021.
Dana is also an advisor of Israeli and USA biotech entities as well as business mentor of Tel Aviv and Bar Ilan Universities, incubators and VCs. Experienced in capital raising, practiced in all sorts of local and EU governmental funding ($10M).
Current Positions
2015 Diagknowstics, CEO
Personalized and Predictive medicine services
Zotal Ltd.
2015 – Head of personalized & predictive medicine
Establish new markets for novel clinical diagnostics & therapeutic drug monitoring in Oncology, Gastro,
Cardio, Psychiatry, Coagulation, Rheumatology. Exclusive distribution agreements, HMO registration.
Genaphora Ltd, V.P. Business Development
2014 – Development and marketing of molecular detection kits for water pathogens using Meta-
genomics data and qPCR.
Bar Ilan University –Faculty of Medicine, Business Mentor
2015 - Business & application mentor of physicians and senior scientists. A leader on numerous
ongoing chief-scientist and European (ERC) grant applications.
BioMarCare Technologies, CEO
2009 – 2014
Company’s founder, inventor and a management member in Micromedic Technologies (controlling
shareholder in BioMarcare Company). BioMarCare was licensed out to MD BioSciences, USA.
Field of activity: Cancer biomarkers for clinical Dx, personalized medicine and companion Dx
(Colorectal and Breast cancers) based on bioinformatics.
Raising of over $2.5 million from investors and funds (bi-national funds, Chief Scientist)
Development of several novel personalized diagnostics products (related to ERBITUX®, AVASTIN®, TAMOXIFEN)
TKsignal, CEO
2005 -2009
Field of Activity: Radio-pharmaceuticals for cancer imaging in Lung (NNCLC) and Head & Neck cancers
(labeled IRESSA®/ TARCIVA®). Pioneering development of radioactive biomarkers for PET/CT imaging
applications in cancer diagnosis.
Raising $3M investment from a UK private investments bank, OCS and Venture Capital Funds
Establishment and management of a TKsignal as a UK public company.
Pronto Diagnostics, Business Development & Marketing Director,
2003 -2005
Field of activity: development, production and sales of IVD kits for the diagnosis of genetic diseases
(Cancer, Pre-Natal screening, Alzheimer).
Founding team. Leading the company through the development and regulation stage to sales.
Savyon Diagnostics Ltd. - Product Manager
2001 –2003
Field of activity: development, manufacturing and sales of Pronto product line (prenatal & genetic
disorders)
GamidaGen Ltd. – R&D, Product manager
1998 –2001 R&D, products management of prenatal diagnosis
Studies and previous experience
1996 MSc (Hons.) Department of Animal Sciences at the Hebrew University, in cooperation with the
Department of Molecular and Quantitative Genetics of Volcani Institute.
Diplomas
Merage fellow-lean launchpad program, Merage Institute, Jan 2021
Good Clinical Practice (GCP) for Investigators / In-Vivo –clinical Quality Services and Hadassah
University Medical Center, Ein Karem, Jerusalem, May 2009
Patents
1. US 61/420,338 Biomarkers for detecting a cancerous state in a subject 07/12/2010
2. US 61/835493 Biomarkers to predict efficacy of EGFR-targeted therapies for colorectal cancer
3. US/ 61/977,636 Methods and kits for identifying both pre-cancerous and CRC state
Publications and Abstracts
1. PAR1 & PAR2 biomarker combination for Breast Cancer DiagnosisPAR1 & PAR2 biomarker combination for Breast Cancer Diagnosis
Tumor Biology, Vol 32. Supplement · 1 janv. 2011Tumor Biology, Vol 32. Supplement · 1 janv. 2011
2. Pronto ThromboRisk - a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia.Pronto ThromboRisk - a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia.
V. J Clin Lab Anal · 1 avr. 2004V. J Clin Lab Anal · 1 avr. 2004
Carmi N, Cohen D, Zvang E, Naparstek E, Deutsch Carmi N, Cohen D, Zvang E, Naparstek E, Deutsch
3. Determination of two mutations in the MCOLN1 gene causing Mucolipidosis type IV, using a primer extension ELISA assayDetermination of two mutations in the MCOLN1 gene causing Mucolipidosis type IV, using a primer extension ELISA assay
ISHG, Israel · 1 janv. 2003ISHG, Israel · 1 janv. 2003
4. FibroTest™: A novel primer extension ELISA assay for the detection of bladder cancer associated mutations in the FGFR3 geneFibroTest™: A novel primer extension ELISA assay for the detection of bladder cancer associated mutations in the FGFR3 gene
EHGC, Birmingham, England · 1 janv. 2003EHGC, Birmingham, England · 1 janv. 2003
5. A novel primer extension assay for Hemochromatosis genotypingA novel primer extension assay for Hemochromatosis genotyping
European Iron Club, Porto, Portugal · 1 janv. 2002European Iron Club, Porto, Portugal · 1 janv. 2002
6. Comparison of two methods for routine accurate determination of the two mutations in the IKBKAP gene causing Familial DysautonomiaComparison of two methods for routine accurate determination of the two mutations in the IKBKAP gene causing Familial Dysautonomia
52nd ASHG, Baltimore, Maryland · 1 janv. 200252nd ASHG, Baltimore, Maryland · 1 janv. 2002
7. Pronto Ethnix™- A population-based approach to genetic testingPronto Ethnix™- A population-based approach to genetic testing
34th ESHG, Strasburg · 1 janv. 200234th ESHG, Strasburg · 1 janv. 2002
8. Thrombophilia and pregnancy: Complications, diagnosis, and treatmentThrombophilia and pregnancy: Complications, diagnosis, and treatment
CLI · 1 janv. 2002CLI · 1 janv. 2002
Cohen. D
9. A novel transgenic marker for migrating limb muscle precursors and for vascular smooth muscle cellsA novel transgenic marker for migrating limb muscle precursors and for vascular smooth muscle cells
Dev Dyn. · 1 janv. 2001Dev Dyn. · 1 janv. 2001
Tidhar A, Reichenstein M, Cohen D, Faerman A, Copeland NG, Gilbert DJ, Jenkins NA, Shani M. Tidhar A, Reichenstein M, Cohen D, Faerman A, Copeland NG, Gilbert DJ, Jenkins NA, Shani M.
10. A unique predictive biomarker, correlated with PET/CT imaging, for aggressive lymphomas monitoring A unique predictive biomarker, correlated with PET/CT imaging, for aggressive lymphomas monitoringA unique predictive biomarker, correlated with PET/CT imaging, for aggressive lymphomas monitoring A unique predictive biomarker, correlated with PET/CT imaging, for aggressive lymphomas monitoring
Abstract - Israel Society of Hematology and Transfusion Medicine, 10,2022
